Neuroderm Ltd Company Profile (NASDAQ:NDRM)

About Neuroderm Ltd (NASDAQ:NDRM)

Neuroderm Ltd logoNeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NDRM
  • CUSIP: N/A
  • Web: www.neuroderm.com
Capitalization:
  • Market Cap: $561 million
  • Outstanding Shares: 26,338,000
Average Prices:
  • 50 Day Moving Avg: $25.43
  • 200 Day Moving Avg: $23.50
  • 52 Week Range: $15.10 - $30.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.40
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.31 per share
  • Price / Book: 4.01
Profitability:
  • EBIDTA: ($40,700,000.00)
  • Return on Equity: -32.12%
  • Return on Assets: -30.45%
Debt:
  • Current Ratio: 15.77%
  • Quick Ratio: 15.77%
Misc:
  • Average Volume: 263,872 shs.
  • Beta: 0.94
  • Short Ratio: 2.03
 

Frequently Asked Questions for Neuroderm Ltd (NASDAQ:NDRM)

What is Neuroderm Ltd's stock symbol?

Neuroderm Ltd trades on the NASDAQ under the ticker symbol "NDRM."

How were Neuroderm Ltd's earnings last quarter?

Neuroderm Ltd (NASDAQ:NDRM) announced its earnings results on Thursday, May, 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.13. View Neuroderm Ltd's Earnings History.

Where is Neuroderm Ltd's stock going? Where will Neuroderm Ltd's stock price be in 2017?

6 analysts have issued twelve-month price objectives for Neuroderm Ltd's shares. Their predictions range from $30.00 to $70.00. On average, they anticipate Neuroderm Ltd's stock price to reach $43.75 in the next twelve months. View Analyst Ratings for Neuroderm Ltd.

What are analysts saying about Neuroderm Ltd stock?

Here are some recent quotes from research analysts about Neuroderm Ltd stock:

  • 1. According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (4/5/2017)
  • 2. Cowen and Company analysts commented, "Neuroderm announced the preliminary Phase II results for ND0612H, and importantly, the initial feedback from our consultants has been very positive. In general, our consultants believe the efficacy looks comparable to Duodopa, but with a significantly improved use and safety profile. These data substantially de-risk the program. The current valuation is dramatically understated." (3/1/2017)

Are investors shorting Neuroderm Ltd?

Neuroderm Ltd saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 1,068,368 shares, an increase of 8.5% from the April 28th total of 984,479 shares. Based on an average daily trading volume, of 203,361 shares, the days-to-cover ratio is currently 5.3 days.

Who are some of Neuroderm Ltd's key competitors?

Who are Neuroderm Ltd's key executives?

Neuroderm Ltd's management team includes the folowing people:

  • Robert Taub, Chairman of the Board
  • Oded S. Liebermann, Chief Executive Officer, Director
  • Roy Golan CPA, Chief Financial Officer
  • Tami Yardeni, Chief Operating Officer
  • Sharon Cohen-Vered Ph.D., Vice President - CMC & QA
  • Sheila Oren, Vice President - Clinical and Regulatory Affairs
  • Eran Shor, Vice President - Devices
  • Oron Yacoby-Zeevi, Vice President - Research & Development
  • Revital Mandil-Levin Ph.D., Head - Business Development
  • Shmuel Cabilly, Director

When did Neuroderm Ltd IPO?

(NDRM) raised $45 million in an initial public offering on Friday, November 14th 2014. The company issued 4,500,000 shares at a price of $10.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

Who owns Neuroderm Ltd stock?

Neuroderm Ltd's stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (3.51%), Menora Mivtachim Holdings LTD. (2.59%), Nexthera Capital LP (1.09%), OppenheimerFunds Inc. (1.09%), FMR LLC (0.76%) and Bailard Inc. (0.41%). View Institutional Ownership Trends for Neuroderm Ltd.

Who sold Neuroderm Ltd stock? Who is selling Neuroderm Ltd stock?

Neuroderm Ltd's stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Menta Capital LLC, Parametric Portfolio Associates LLC, Victory Capital Management Inc., Swiss National Bank, Renaissance Technologies LLC, Bank of America Corp DE and Morgan Stanley. View Insider Buying and Selling for Neuroderm Ltd.

Who bought Neuroderm Ltd stock? Who is buying Neuroderm Ltd stock?

Neuroderm Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, OppenheimerFunds Inc., FMR LLC, Menora Mivtachim Holdings LTD., Credit Suisse AG, NJ State Employees Deferred Compensation Plan, Bank of Montreal Can and Bailard Inc.. View Insider Buying and Selling for Neuroderm Ltd.

How do I buy Neuroderm Ltd stock?

Shares of Neuroderm Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuroderm Ltd's stock price today?

One share of Neuroderm Ltd stock can currently be purchased for approximately $21.30.


MarketBeat Community Rating for Neuroderm Ltd (NASDAQ NDRM)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Neuroderm Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neuroderm Ltd (NASDAQ:NDRM) (?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $43.75 (105.40% upside)

Analysts' Ratings History for Neuroderm Ltd (NASDAQ:NDRM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/14/2017Oppenheimer Holdings Inc.Reiterated RatingHoldMediumView Rating Details
4/24/2017Jefferies Group LLCReiterated RatingBuy$42.00HighView Rating Details
4/1/2017Roth CapitalSet Price TargetBuy$33.00HighView Rating Details
3/7/2017CIBCReiterated RatingOutperform -> Market PerformN/AView Rating Details
3/7/2017Citigroup IncDowngradeOutperform -> Market PerformN/AView Rating Details
3/1/2017Cowen and CompanyBoost Price TargetOutperform$38.00 -> $70.00N/AView Rating Details
11/10/2015Raymond James Financial, Inc.Initiated CoverageOutperform$28.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Neuroderm Ltd (NASDAQ:NDRM)
Earnings by Quarter for Neuroderm Ltd (NASDAQ:NDRM)
Earnings History by Quarter for Neuroderm Ltd (NASDAQ:NDRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.38)($0.25)ViewN/AView Earnings Details
3/30/201712/31/2016($0.46)($0.49)ViewN/AView Earnings Details
11/10/20169/30/2016($0.42)($0.42)ViewN/AView Earnings Details
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)($0.31)ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.07)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015Q4 2014($0.35)($2.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neuroderm Ltd (NASDAQ:NDRM)
2017 EPS Consensus Estimate: ($1.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.40)($0.40)($0.40)
Q2 20172($0.51)($0.40)($0.46)
Q3 20172($0.51)($0.50)($0.51)
Q4 20172($0.50)($0.50)($0.50)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Neuroderm Ltd (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Neuroderm Ltd (NASDAQ:NDRM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Neuroderm Ltd (NASDAQ:NDRM)
Latest Headlines for Neuroderm Ltd (NASDAQ:NDRM)
Source:
DateHeadline
americanbankingnews.com logoNeuroderm Ltd (NDRM) Short Interest Update
www.americanbankingnews.com - May 29 at 7:56 AM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 26 at 11:13 AM
streetinsider.com logoNeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress - StreetInsider.com
www.streetinsider.com - May 24 at 6:53 PM
streetinsider.com logoNeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress
www.streetinsider.com - May 24 at 10:29 AM
finance.yahoo.com logoNeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
finance.yahoo.com - May 23 at 10:15 AM
americanbankingnews.com logo Analysts Anticipate Neuroderm Ltd (NDRM) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - May 17 at 4:18 PM
americanbankingnews.com logoNeuroderm Ltd to Post Q2 2017 Earnings of ($0.51) Per Share, Oppenheimer Holdings Forecasts (NDRM)
www.americanbankingnews.com - May 17 at 7:46 AM
americanbankingnews.com logoFY2019 Earnings Estimate for Neuroderm Ltd (NDRM) Issued By Oppenheimer Holdings
www.americanbankingnews.com - May 16 at 1:26 PM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Issues Earnings Results
www.americanbankingnews.com - May 11 at 3:00 PM
cnbc.com logoNeuroDerm reports 1Q loss
www.cnbc.com - May 11 at 9:28 AM
finance.yahoo.com logoNeuroDerm Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 9:28 AM
americanbankingnews.com logoNeuroderm (NDRM) Earns Daily Media Impact Rating of -0.09
www.americanbankingnews.com - May 4 at 12:06 PM
americanbankingnews.com logoNeuroderm (NDRM) Receiving Favorable Media Coverage, Report Finds
www.americanbankingnews.com - May 1 at 4:56 PM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 1 at 2:32 PM
americanbankingnews.com logoNeuroderm (NDRM) Earns Media Impact Score of -0.20
www.americanbankingnews.com - April 27 at 3:08 PM
americanbankingnews.com logoZacks: Analysts Expect Neuroderm Ltd (NDRM) to Announce -$0.38 Earnings Per Share
www.americanbankingnews.com - April 27 at 1:11 AM
americanbankingnews.com logoFY2017 EPS Estimates for Neuroderm Ltd (NDRM) Reduced by Jefferies Group
www.americanbankingnews.com - April 26 at 1:12 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for Neuroderm Ltd (NDRM)
www.americanbankingnews.com - April 24 at 10:10 PM
americanbankingnews.com logoNeuroderm (NDRM) Earning Positive News Coverage, Study Finds
www.americanbankingnews.com - April 24 at 4:32 PM
americanbankingnews.com logoNeuroderm's (NDRM) Hold Rating Reaffirmed at Oppenheimer Holdings Inc.
www.americanbankingnews.com - April 23 at 11:52 PM
nasdaq.com logoNeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell - Nasdaq
www.nasdaq.com - April 22 at 6:11 PM
finance.yahoo.com logoNeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk
finance.yahoo.com - April 20 at 6:52 PM
finance.yahoo.com logoNeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - April 20 at 6:52 PM
americanbankingnews.com logoNeuroderm (NDRM) Receiving Critical News Coverage, Report Shows
www.americanbankingnews.com - April 20 at 8:45 AM
finance.yahoo.com logoPost Earnings Coverage as NeuroDerm Reported FY16 Results
finance.yahoo.com - April 12 at 9:13 AM
finance.yahoo.com logoNeuroDerm to Host Investor Day on April 21, 2017
finance.yahoo.com - April 10 at 10:15 AM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Expected to Announce Quarterly Sales of $0.00
www.americanbankingnews.com - April 7 at 9:01 PM
finance.yahoo.com logoNeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - April 7 at 11:27 AM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:52 PM
americanbankingnews.com logo-$0.38 EPS Expected for Neuroderm Ltd (NDRM) This Quarter
www.americanbankingnews.com - April 5 at 4:07 PM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 2:00 PM
americanbankingnews.com logoNeuroderm Ltd Expected to Earn Q2 2017 Earnings of ($0.42) Per Share (NDRM)
www.americanbankingnews.com - April 3 at 8:56 AM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Given a $33.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - April 2 at 11:30 PM
finance.yahoo.com logoNeuroDerm reports 4Q loss
finance.yahoo.com - March 30 at 7:05 PM
finance.yahoo.com logoNeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 30 at 7:05 PM
finance.yahoo.com logo7:05 am NeuroDerm reports Q4 results; remains on track to submit regulatory applications for ND0612 in the U.S. and EU in 2018
finance.yahoo.com - March 30 at 7:05 PM
biz.yahoo.com logoQ4 2016 Neuroderm Ltd Earnings Release - Before Market Open
biz.yahoo.com - March 30 at 7:05 PM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Announces Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - March 30 at 9:49 AM
americanbankingnews.com logoNeuroderm's (NDRM) "Buy" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - March 30 at 8:19 AM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 28 at 8:23 AM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - March 25 at 7:50 AM
finance.yahoo.com logoNeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017
finance.yahoo.com - March 21 at 11:34 AM
americanbankingnews.com logoNeuroderm Ltd (NDRM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 7 at 10:39 PM
us.rd.yahoo.com logoNeuroDerm downgraded by Oppenheimer
us.rd.yahoo.com - March 7 at 6:37 PM
finance.yahoo.com logoCan The Uptrend Continue for NeuroDerm (NDRM)?
finance.yahoo.com - March 7 at 10:11 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Infrastructure stocks, Dynavax, NeuroDerm - Nasdaq
www.nasdaq.com - March 3 at 12:00 AM
streetinsider.com logoNeuroDerm's (NDRM) Phase II Trial of ND0612H in Parkinson's Achieves Primary Endpoint - StreetInsider.com
www.streetinsider.com - March 3 at 12:00 AM
nasdaq.com logoHealth Care Sector Update for 03/01/2017: NDRM,DVAX,IPXL - Nasdaq
www.nasdaq.com - March 3 at 12:00 AM
us.rd.yahoo.com logo7:00 am NeuroDerm achieves primary endpoint in ND0612H Phase II Trial for advanced parkinson's disease; seeks broader EU Label Based on iNDiGO trial following EMA meeting (shares halted)
us.rd.yahoo.com - March 2 at 6:59 PM
rttnews.com logoNeuroDerm Ltd. (NDRM) Soared To A New High On Phase 2 Study Results
www.rttnews.com - March 2 at 9:15 AM

Social

Chart

Neuroderm Ltd (NDRM) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff